Boundless Bio Inc (BOLD)

$1.52 -0.03 (-1.94%)
Market Cap 34.73M
Revenue (ttm) 0.00
Net Income (ttm) -58.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 95,600
Avg Vol 227,750
Day's Range N/A - N/A
Shares Out 22.41M
Stochastic %K 71%
Beta -0.86
Analysts Hold
Price Target $4.00

Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor s...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 766 9912
Address:
10955 Alexandria Way, Suite 100, San Diego, United States
AlphaBull_10M
AlphaBull_10M Apr. 24 at 1:55 AM
$BOLD $KOLD $KORU $UVIX $BTC
0 · Reply
vu_jade
vu_jade Apr. 22 at 2:04 PM
$BOLD nice consolidation
0 · Reply
focafoca99
focafoca99 Apr. 17 at 8:54 PM
$BOLD Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting https://www.rapidticker.com/news/bold-boundless-bio-presents-preclinical-breast-8da716
0 · Reply
uptrend2025
uptrend2025 Apr. 17 at 7:16 PM
$BOLD Cancer presentation this weekend 👀
0 · Reply
Golibajje
Golibajje Apr. 15 at 10:57 PM
$BOLD Along with this $BOLT is another lottery ticket in the making! It is trading nearly 1/4th of cash (low float with 1.9m shares.. $9M mkt cap vs $31M cash).. they have phase 1 results in Q3.. disruptive treatment in BILLION $$ mkt! Could go 500%+ if the results are positive! $ZNTL $ALMS
0 · Reply
Golibajje
Golibajje Apr. 15 at 3:54 PM
$BOLD breakout in 2-3 days!!
0 · Reply
revuelto
revuelto Apr. 14 at 9:20 PM
$BOLD = GOLD 🎉
0 · Reply
vu_jade
vu_jade Apr. 14 at 7:52 PM
$BOLD & the beautiful Everyone will saybthey bought at $1 We have receipts .. See you at $5, $8, $10 & $16
1 · Reply
revuelto
revuelto Apr. 14 at 6:21 PM
$BOLD there’s a reason for that 5.5m volume..welcome to the la la land soon 🎉
0 · Reply
Galaxytrader
Galaxytrader Apr. 14 at 6:17 PM
$BOLD $3 by tomorrow!
0 · Reply
Latest News on BOLD
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Apr 17, 2026, 4:49 PM EDT - 6 days ago

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Mar 17, 2026, 4:52 PM EDT - 5 weeks ago

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 7:00 AM EDT - 6 weeks ago

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Mar 4, 2026, 7:00 AM EST - 7 weeks ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 2 months ago

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Jan 20, 2026, 7:00 AM EST - 3 months ago

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 5 months ago

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 5, 2025, 7:00 AM EST - 6 months ago

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 6 months ago

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 7:00 AM EDT - 9 months ago

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 4:58 PM EDT - 11 months ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Boundless Bio Announces Portfolio Prioritization and Runway Extension

May 23, 2025, 4:01 PM EDT - 11 months ago

Boundless Bio Announces Portfolio Prioritization and Runway Extension

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Apr 3, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Feb 3, 2025, 10:00 AM EST - 1 year ago

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Boundless Bio Announces Pipeline and Leadership Updates

Dec 12, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Announces Pipeline and Leadership Updates

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 7, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Nov 5, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

May 13, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Boundless Bio Announces Pricing of Initial Public Offering

Mar 27, 2024, 6:55 PM EDT - 2 years ago

Boundless Bio Announces Pricing of Initial Public Offering

AlphaBull_10M
AlphaBull_10M Apr. 24 at 1:55 AM
$BOLD $KOLD $KORU $UVIX $BTC
0 · Reply
vu_jade
vu_jade Apr. 22 at 2:04 PM
$BOLD nice consolidation
0 · Reply
focafoca99
focafoca99 Apr. 17 at 8:54 PM
$BOLD Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting https://www.rapidticker.com/news/bold-boundless-bio-presents-preclinical-breast-8da716
0 · Reply
uptrend2025
uptrend2025 Apr. 17 at 7:16 PM
$BOLD Cancer presentation this weekend 👀
0 · Reply
Golibajje
Golibajje Apr. 15 at 10:57 PM
$BOLD Along with this $BOLT is another lottery ticket in the making! It is trading nearly 1/4th of cash (low float with 1.9m shares.. $9M mkt cap vs $31M cash).. they have phase 1 results in Q3.. disruptive treatment in BILLION $$ mkt! Could go 500%+ if the results are positive! $ZNTL $ALMS
0 · Reply
Golibajje
Golibajje Apr. 15 at 3:54 PM
$BOLD breakout in 2-3 days!!
0 · Reply
revuelto
revuelto Apr. 14 at 9:20 PM
$BOLD = GOLD 🎉
0 · Reply
vu_jade
vu_jade Apr. 14 at 7:52 PM
$BOLD & the beautiful Everyone will saybthey bought at $1 We have receipts .. See you at $5, $8, $10 & $16
1 · Reply
revuelto
revuelto Apr. 14 at 6:21 PM
$BOLD there’s a reason for that 5.5m volume..welcome to the la la land soon 🎉
0 · Reply
Galaxytrader
Galaxytrader Apr. 14 at 6:17 PM
$BOLD $3 by tomorrow!
0 · Reply
revuelto
revuelto Apr. 14 at 3:21 PM
$BOLD how about $2+ ah today? 🐋
0 · Reply
Dirk1969
Dirk1969 Apr. 14 at 2:49 PM
$BOLD 👇🏽
0 · Reply
intrader
intrader Apr. 14 at 2:47 PM
$BOLD I took 90% off here. Let the rest run.
0 · Reply
Play_Nice69
Play_Nice69 Apr. 14 at 2:26 PM
$BOLD If this breaks 1.80…
0 · Reply
intrader
intrader Apr. 14 at 2:26 PM
$BOLD I'm in, Target $2.00+
0 · Reply
nf04
nf04 Apr. 14 at 2:21 PM
$BOLD bought on Friday for 1.15 in anticipation of the upcoming AACR poster. Early leak?
1 · Reply
Play_Nice69
Play_Nice69 Apr. 14 at 2:18 PM
$SNAL $BOLD nice breakout👌
0 · Reply
slacktime
slacktime Apr. 14 at 2:13 PM
$BOLD might as well test the 52W high while we are at it!
0 · Reply
MKRReformed
MKRReformed Apr. 14 at 1:59 PM
$BOLD finally starting to break out
1 · Reply
Golibajje
Golibajje Apr. 14 at 1:52 PM
$BOLD Sold 17k shares for $1.49.. will reenter after 2-3 days under $1.20!
1 · Reply
revuelto
revuelto Apr. 14 at 1:43 PM
$BOLD I think this is going to show a move today….don’t exit too early 😀
0 · Reply
mbarelorenzo
mbarelorenzo Apr. 14 at 1:41 PM
$BOLD IDEA LONG AT 1.6
0 · Reply